Pharmacogenomics

What is Pharmacogenomics?

Pharmacogenomics (PGx) is the study of how your genes affect your response to medications. By analyzing specific genes involved in drug metabolism, transport, and target interactions, we can predict:

Drug Efficacy: Will this medication work for you?
Optimal Dosing: What dose is right for your genetic makeup?
Adverse Reactions: Are you at risk for side effects?
Drug-Drug Interactions: How will multiple medications interact?

Genetic variations can result in different metabolizer phenotypes: poor, intermediate, extensive, or ultrarapid metabolizers. This information guides clinicians to select the right drug at the right dose for each patient.

Pharmacogenomics - Personalized Medicine

Key Pharmacogenomic Concepts

Understanding metabolizer phenotypes

Poor Metabolizer

Reduced or absent enzyme activity leads to slow drug clearance, increasing risk of toxicity and adverse effects. May require lower doses or alternative medications.

Poor Metabolizer

Intermediate Metabolizer

Reduced enzyme activity compared to normal. May require dose adjustments or careful monitoring for optimal therapeutic response.

Intermediate Metabolizer

Extensive Metabolizer

Normal enzyme activity - the "wild-type" or reference phenotype. Standard dosing is typically appropriate.

Extensive Metabolizer

Ultrarapid Metabolizer

Increased enzyme activity leads to rapid drug clearance, potentially reducing efficacy. May require higher doses or alternative medications.

Ultrarapid Metabolizer

CYP450 Enzymes

The cytochrome P450 family of enzymes metabolizes over 70-80% of all medications. Key genes include CYP2D6, CYP2C19, CYP2C9, CYP3A4, and CYP3A5.

Drug Transporters

Genes like SLCO1B1 affect drug uptake into cells, influencing drug levels and risk of toxicity (e.g., statin-induced myopathy).

Common Drug-Gene Interactions

Examples of clinically actionable PGx associations

Clopidogrel (Plavix)

Antiplatelet

CYP2C19

Poor metabolizers have reduced activation, leading to higher risk of cardiovascular events. Alternative therapy recommended.

Warfarin (Coumadin)

Anticoagulant

CYP2C9, VKORC1

Variants affect metabolism and sensitivity. Genotype-guided dosing reduces bleeding risk and time to therapeutic INR.

SSRIs (Citalopram)

Antidepressants

CYP2C19

Poor metabolizers have increased drug levels, risk of QT prolongation. Ultrarapid metabolizers may have reduced efficacy.

Codeine

Opioid Analgesic

CYP2D6

Ultrarapid metabolizers convert more codeine to morphine, risking toxicity. Poor metabolizers get no pain relief.

Statins (Simvastatin)

Lipid-lowering

SLCO1B1

Reduced function variants increase risk of statin-induced myopathy and rhabdomyolysis.

5-FU / Capecitabine

Chemotherapy

DPYD

Reduced DPD enzyme activity leads to severe, potentially fatal toxicity. Testing required before treatment.

Carbamazepine

Anticonvulsant

HLA-B*1502

Asian populations with this variant are at high risk for Stevens-Johnson syndrome. Screening required.

Azathioprine

Immunosuppressant

TPMT, NUDT15

Poor metabolizers risk severe myelosuppression. Dose reduction or alternative therapy recommended.

Benefits of Pharmacogenomic Testing

How PGx improves patient care

Improved Efficacy

Select medications most likely to work based on your genetic profile, reducing trial-and-error prescribing.

Reduced Adverse Reactions

Avoid medications that may cause toxicity or side effects, improving safety and patient compliance.

Optimal Dosing

Start with the right dose from day one, avoiding subtherapeutic or toxic levels.

Cost Savings

Reduce healthcare costs by avoiding ineffective medications, hospitalizations from adverse reactions, and unnecessary clinic visits.

Faster Time to Response

Achieve therapeutic goals more quickly by selecting the right medication and dose from the start.

Lifetime Value

Genetic results are valid for life and can guide future medication decisions as new drugs become available.

Pharmacogenomic Testing Panels

Comprehensive options for different clinical needs

Comprehensive PGx Panel

20+ genes | 200+ medications

CYP2D6 - Antidepressants, antipsychotics, opioids
CYP2C19 - Clopidogrel, SSRIs, PPIs
CYP2C9 - Warfarin, NSAIDs, phenytoin
CYP3A4/5 - Statins, calcium channel blockers
SLCO1B1 - Statin-induced myopathy risk
VKORC1 - Warfarin sensitivity
TPMT, NUDT15 - Thiopurine toxicity
DPYD - Fluoropyrimidine toxicity

Cardiology PGx Panel

12 genes | 50+ cardiovascular drugs

CYP2C19 - Clopidogrel response
CYP2C9 + VKORC1 - Warfarin dosing
SLCO1B1 - Statin myopathy risk
CYP3A4/5 - Calcium channel blockers
CYP2D6 - Beta-blockers (metoprolol)
ADRB1 - Beta-blocker response
ACE, AGT - ACE inhibitor response

Psychiatry PGx Panel

15 genes | 80+ psychiatric medications

CYP2D6 - SSRIs, SNRIs, antipsychotics
CYP2C19 - Citalopram, sertraline
CYP3A4 - Aripiprazole, quetiapine
COMT - Dopamine metabolism
HTR2A, SLC6A4 - Antidepressant response
MTHFR - Folate metabolism
HLA-A, HLA-B - Hypersensitivity risk

Pain Management Panel

10 genes | 40+ analgesics

CYP2D6 - Codeine, tramadol, oxycodone
CYP2C9 - NSAIDs (ibuprofen, celecoxib)
CYP3A4 - Fentanyl, methadone
OPRM1 - Opioid receptor sensitivity
COMT - Pain perception
GRIK4 - Treatment-resistant depression

Oncology PGx Panel

15 genes | 30+ chemotherapy drugs

DPYD - 5-FU, capecitabine toxicity
TPMT, NUDT15 - Thiopurine toxicity
UGT1A1 - Irinotecan toxicity
CYP2D6 - Tamoxifen metabolism
CYP3A5 - Vincristine, taxanes
G6PD - Rasburicase hemolytic risk

Custom PGx Panel

Flexible design

Custom panels designed based on specific medication classes or clinical indications. Contact our genetic counselors to discuss your requirements.

Flexible Targeted Cost-effective

Evidence-Based Guidelines

Clinical Pharmacogenetics Implementation Consortium (CPIC)

Our testing and reporting follow CPIC guidelines, the international standard for translating pharmacogenomic results into actionable prescribing recommendations. Each report includes CPIC-based therapeutic recommendations.

CPIC Guidelines

FDA Table of Pharmacogenomics

DPWG Guidelines

Pharmacogenomic testing benefits many patient populations

Starting New Medications

Antidepressants or antipsychotics
Cardiovascular medications
Pain management
Chemotherapy

Poor Response to Medications

Multiple medication trials
Inadequate therapeutic response
Frequent medication changes

Adverse Drug Reactions

History of side effects
Family history of ADRs
Multiple medications

Chronic Disease Management

Cardiovascular disease
Psychiatric conditions
Chronic pain
Cancer

Polypharmacy

Taking 5+ medications
Elderly patients
Complex medication regimens

Pre-emptive Testing

Results valid for lifetime
Future medication decisions
Family planning

Frequently Asked Questions

Common questions about pharmacogenomic testing

Do I need a new test for each medication?

No. Once you have pharmacogenomic testing, the results are valid for your lifetime and can guide decisions for many medications across different drug classes.

What sample is required?

Both blood (3-5 mL EDTA tube) and saliva samples are acceptable. Saliva kits can be mailed directly to patients for convenient at-home collection.

How long does it take to get results?

Most pharmacogenomic tests have a turnaround time of 7-10 business days from sample receipt at the laboratory.

Will my doctor know how to use these results?

Our reports include CPIC-based therapeutic recommendations in an easy-to-understand format. We also offer genetic counselor consultations for healthcare providers.

Does insurance cover PGx testing?

Many insurance plans cover pharmacogenomic testing for specific indications. Our team can assist with pre-authorization and insurance verification.

Do results change over time?

Your genetic results are stable throughout life. However, as new evidence emerges, recommendations for specific drugs may be updated. We offer re-analysis services as guidelines evolve.

What is Pharmacogenomics?

Key Pharmacogenomic Concepts

Poor Metabolizer

Intermediate Metabolizer

Extensive Metabolizer

Ultrarapid Metabolizer

CYP450 Enzymes

Drug Transporters

Common Drug-Gene Interactions

Clopidogrel (Plavix)

Warfarin (Coumadin)

SSRIs (Citalopram)

Codeine

Statins (Simvastatin)

5-FU / Capecitabine

Carbamazepine

Azathioprine

Benefits of Pharmacogenomic Testing

Improved Efficacy

Reduced Adverse Reactions

Optimal Dosing

Cost Savings

Faster Time to Response

Lifetime Value

Pharmacogenomic Testing Panels

Comprehensive PGx Panel

Cardiology PGx Panel

Psychiatry PGx Panel

Pain Management Panel

Oncology PGx Panel

Custom PGx Panel

Clinical Pharmacogenetics Implementation Consortium (CPIC)

Featured Pharmacogenomic Tests

CYP2C19 Genotyping (Clopidogrel Metabolism)

CYP2C9 Genotyping

DPYD Genotyping